Arizona Tribune - Aspira Women's Health Wins Laboratory Service Contract with University of Texas Medical Branch at Galveston

AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / October 29, 2025 / Aspira Women's Health Inc., abio-analytical-based women's health company focused on gynecologic disease diagnostics, today announced it has executed a new laboratory services agreement with University of Texas Medical Branch at Galveston ("UTMB Galveston"), a part of the University of Texas System.

The initial term of the agreement is 12 months and is part of the Company's redefined marketing strategy that has prioritized marketing the Company's health care solutions to larger organizations that enable Aspira to efficiently reach thousands of potential patients and their care providers with each new platform adoption. With this new lab services agreement the Company has taken meaningful steps to reach new patients in the Texas market for its Ova1Plus® and OvaWatch® products.

"I am pleased to announce such a prestigious new client addition on behalf of our team," commented Mike Buhle, CEO of Aspira. "One of our top priorities has been to transform and improve our go-to-market strategy. We are extremely focused on growing our Ova1Plus® and OvaWatch® revenues in the most efficient, accelerated way possible. Our partnership with University of Texas Medical Branch at Galveston is an excellent example of how we aim to quickly leverage technology and strategic relationships to reach more patients and positively impact women's health."

About Aspira Women's Health Inc. 

Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.  OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuite^SM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year.

OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery.     

Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.

Forward-Looking Statements 

This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "designed to," "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including those factors identified as "Risk Factors" in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. 

Investor Relations Contact: 
[email protected]

SOURCE: Aspira Women's Health

View the original press release on ACCESS Newswire

E.Rodriguez--AT